Venus Medtech (Hangzhou) Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Venus Medtech (Hangzhou) şirketinin toplam hissedar öz sermayesi CN¥2.9B ve toplam borcu CN¥705.9M olup, bu da borç-öz sermaye oranını 24.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥4.4B ve CN¥1.5B dir.

Anahtar bilgiler

24.2%

Borç/özkaynak oranı

CN¥705.91m

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥781.64m
Eşitlik	CN¥2.92b
Toplam yükümlülükler	CN¥1.49b
Toplam varlıklar	CN¥4.41b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: VMTH.F 'nin kısa vadeli varlıkları ( CN¥1.6B ) kısa vadeli yükümlülüklerini ( CN¥805.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: VMTH.F şirketinin kısa vadeli varlıkları ( CN¥1.6B ) uzun vadeli yükümlülüklerini ( CN¥689.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: VMTH.F şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: VMTH.F şirketinin borç/öz sermaye oranı son 5 yılda 17% seviyesinden 24.2% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: VMTH.F şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: VMTH.F un, serbest nakit akışı her yıl % 28.4 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Venus Medtech (Hangzhou) Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

Venus Medtech (Hangzhou) Inc. Announces Executive Changes

Venus Medtech (Hangzhou) Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023

Venus Medtech (Hangzhou) Inc. to Report First Half, 2023 Results on Aug 31, 2023

Venus Medtech (Hangzhou) Inc., Annual General Meeting, Jun 30, 2023

Venus Medtech (Hangzhou) Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary

Venus Medtech (Hangzhou) Inc. Announces Board Changes

Venus Medtech (Hangzhou) Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

Venus Medtech (Hangzhou) Inc. to Report First Half, 2022 Results on Aug 31, 2022

China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System

Venus Medtech (Hangzhou) Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use

Venus Medtech (Hangzhou) Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application

Venus Medtech (Hangzhou) Inc., Annual General Meeting, May 30, 2022

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2021 Results on Mar 31, 2022

Venus Medtech (Hangzhou) Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation Center

Venus Medtech (Hangzhou) Inc. Announces Completion of Global First Clinical Application of Venus-Powerx

Venus Medtech (Hangzhou) Inc. Announces Venus Vitae, Balloon-Expandable Dry Tissue Tavr System Successfully Completed the First Two Implantations in the Fim Clinical Trial

Venus Medtech (Hangzhou) Inc. (SEHK:2500) commences an Equity Buyback Plan for 43,170,744 shares, representing 9.79% of its issued share capital, under the authorization approved on May 21, 2021.

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2020 Results on Mar 31, 2021

Venus Medtech (Hangzhou) Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.444843 billion.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin